Novo Nordisk A/S (NYSE:NVO) Shares Sold by Stratos Wealth Partners LTD.

Stratos Wealth Partners LTD. reduced its position in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 36.9% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 15,993 shares of the company's stock after selling 9,368 shares during the period. Stratos Wealth Partners LTD.'s holdings in Novo Nordisk A/S were worth $1,111,000 as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. Stratos Investment Management LLC grew its holdings in shares of Novo Nordisk A/S by 63.2% in the 1st quarter. Stratos Investment Management LLC now owns 84,046 shares of the company's stock worth $5,836,000 after acquiring an additional 32,559 shares during the period. May Hill Capital LLC raised its position in shares of Novo Nordisk A/S by 79.7% in the first quarter. May Hill Capital LLC now owns 8,753 shares of the company's stock valued at $608,000 after buying an additional 3,883 shares during the last quarter. NTV Asset Management LLC lifted its stake in shares of Novo Nordisk A/S by 8.1% during the first quarter. NTV Asset Management LLC now owns 9,954 shares of the company's stock valued at $691,000 after buying an additional 748 shares during the period. Hourglass Capital LLC boosted its position in Novo Nordisk A/S by 9.9% during the first quarter. Hourglass Capital LLC now owns 20,820 shares of the company's stock worth $1,446,000 after acquiring an additional 1,870 shares during the last quarter. Finally, Walter Public Investments Inc. boosted its position in Novo Nordisk A/S by 5.5% during the first quarter. Walter Public Investments Inc. now owns 209,977 shares of the company's stock worth $14,581,000 after acquiring an additional 10,920 shares during the last quarter. Hedge funds and other institutional investors own 11.54% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on the company. Hsbc Global Res raised Novo Nordisk A/S to a "strong-buy" rating in a research note on Monday, April 28th. Guggenheim cut Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a report on Thursday, April 17th. Dbs Bank downgraded shares of Novo Nordisk A/S to a "sell" rating in a research report on Friday, April 25th. Wall Street Zen upgraded shares of Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research note on Saturday, June 14th. Finally, BNP Paribas began coverage on shares of Novo Nordisk A/S in a research note on Tuesday, April 15th. They issued an "underperform" rating on the stock. Two investment analysts have rated the stock with a sell rating, five have issued a hold rating, four have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of "Hold" and an average price target of $112.00.

Novo Nordisk A/S Stock Down 0.2%

Shares of NVO stock traded down $0.14 on Wednesday, hitting $67.08. The stock had a trading volume of 5,592,285 shares, compared to its average volume of 9,202,784. The stock's 50 day moving average is $70.37 and its 200-day moving average is $74.73. The firm has a market capitalization of $299.50 billion, a price-to-earnings ratio of 19.85, a P/E/G ratio of 1.33 and a beta of 0.64. Novo Nordisk A/S has a 52-week low of $57.00 and a 52-week high of $139.74. The company has a debt-to-equity ratio of 0.70, a quick ratio of 0.56 and a current ratio of 0.74.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last issued its quarterly earnings data on Wednesday, May 7th. The company reported $0.92 earnings per share for the quarter, meeting analysts' consensus estimates of $0.92. Novo Nordisk A/S had a return on equity of 80.94% and a net margin of 34.52%. The firm had revenue of $11.87 billion during the quarter. As a group, research analysts expect that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.